Delfi Diagnostics
Blood test. Early lung cancer detection.
Baltimore, MD, US
Delfi Diagnostics focuses on early cancer detection using machine learning.
How We Help
Problem Statement
Cancer kills 10 million people per year, early detection is key to improving outcomes.
Core Technology
Fragmented DNA patterns in blood plasma, machine learning
Key Differentiators
Uses fragmented DNA patterns in blood plasma
Clinical Focus
Oncology; Early Detection
Company Info
- Business Model
- B2B
- Founded
- 2019
- Total Funding
- 330,000,000
- Website
- www.delfidiagnostics.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
FirstLook Lung validated in Cancer Discovery (2024) with 80% sensitivity, 99.8% NPV. Nature publication (2019). FDA breakthrough device designation (2021). CASCADE-LUNG prospective trial ongoing.
MedStartr Index Score
?What do you think of Delfi Diagnostics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.